Author
Listed:
- A. Hossin
(Khulna University, Bangladesh)
- B. Chakma
(Khulna University, Bangladesh)
- M. A. I. Raju
(Khulna University, Bangladesh)
Abstract
The current study was conducted to verify the traditional medicinal use and to carry out the in-vitro antioxidant activity of various solvent extracts of Derris trifoliata (aerial part). The percentage yield of ethanol, ethyl acetate and n-hexane extracts were found 2.5% w/w. Freshly prepared extracts were subjected to preliminary phytochemical screening. All extracts revealed the presence of several important phytochemicals which might be responsible for its medicinal properties. In vitro Electron transfer (ET) reaction-based assays of ethanol, ethyl acetate and n-hexane extracts have been investigated using various model systems viz., DPPH, total phenolic, tannin and flavonoid content, ferric ion reducing antioxidant power (FRAP) and reducing power assay. Hydrogen atom transfer (HAT) reaction-based assays have been conducted using Nitric Oxide (NO) scavenging and hydrogen peroxide scavenging activity assay methods. Ethanol extract was found to possess highest DPPH (IC50=16.824 µg/ml), total phenolic content (44.51 GAE/g of dried plant extract), reducing power assay (0.387±0.0006), FRAF assay (IC50=133.51 µg/ml), hydrogen peroxide scavenging (IC50=144.888 µg/ml) and nitric oxide scavenging activities (IC50=152.655 µg/ml). Whereas ethyl acetate extract was found to possess the highest total tannin content (42.56 GAE/g of dried plant extract) and total flavonoid content (78.08 QE/g of dried plant extract). In vitro antioxidant study was also performed in terms of chelation power on ferrous ions. The highest chelation power was found for ethyl acetate extract (IC50=62.489 µg/ml). The above study suggests that Derris trifoliata may be a vital source of nutraceuticals.
Suggested Citation
Handle:
RePEc:epw:pharma:v:1:y:2021:i:1:id:704
DOI: 10.24018/ejpharma.2021.1.1.4
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:pharma:v:1:y:2021:i:1:id:704. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/pharma .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.